Are the TSH of 1.5 mIU/L and free thyroxine of 5.1 µg/dL appropriate for a patient taking levothyroxine (Synthroid) 75 µg daily and liothyronine (Cytomel) 10 µg daily?

Assessment of Current Thyroid Levels

Your TSH of 1.52 mIU/L is optimal and your free thyroxine of 5.1 µg/dL is critically abnormal—this value is either a laboratory error or indicates severe overtreatment requiring immediate dose reduction.

Critical Issue with Free Thyroxine Value

The reported free thyroxine (FT4) of 5.1 µg/dL is extraordinarily high and incompatible with the TSH of 1.52 mIU/L. To put this in perspective:

• Normal FT4 reference range is typically 0.8-1.8 ng/dL (or 10-23 pmol/L)
• Your reported value of 5.1 µg/dL would be 5,100 ng/dL—approximately 2,800 times the upper limit of normal
• This level would cause severe thyrotoxicosis with TSH completely suppressed to <0.01 mIU/L, not 1.52 mIU/L

Most likely explanation: The unit is incorrectly reported. If this is actually 5.1 pmol/L, this would be severely LOW (hypothyroid). If it's 1.5 ng/dL (transposed digits), this would be normal.

If Assuming Normal FT4 Range

Your TSH of 1.52 mIU/L represents excellent control on combination therapy. 1

Why This TSH is Optimal

According to AACE/ATA guidelines, the target TSH for treated hypothyroidism should fall within the normal reference range of 0.45-4.12 mIU/L 1. Your TSH of 1.52 mIU/L:

• Matches the mean and median TSH of approximately 1.5 mIU/L seen in healthy euthyroid individuals 1
• Falls comfortably within the therapeutic target range
• Indicates appropriate dosing without overtreatment

Combination Therapy Considerations

Your regimen of levothyroxine 75 mcg + liothyronine 10 mcg is non-standard but acceptable in specific circumstances:

When combination therapy may be appropriate 2, 3:

• Persistent symptoms despite optimized levothyroxine monotherapy with TSH 0.3-2.0 mIU/L for 3-6 months
• Confirmed overt hypothyroidism (not subclinical)
• Other causes of symptoms excluded
• Shared decision-making between patient and clinician

Important caveats about liothyronine 4:

• The FDA-approved usual maintenance dose is 25-75 mcg daily for monotherapy
• Your 10 mcg dose is relatively low and appropriate for combination use
• Liothyronine causes wide swings in serum T3 levels and carries greater cardiovascular risk than levothyroxine alone 4
• Most randomized trials show no advantage of combination therapy over levothyroxine monotherapy 2, 3

Monitoring Recommendations

TSH is the primary endpoint for monitoring 1. With your current TSH of 1.52 mIU/L:

• No dose adjustment needed if you feel well clinically
• Recheck TSH in 6-12 months once stable 1
• FT4 and FT3 levels are not necessary for dose titration when TSH is in normal range 1

Red Flags Requiring Dose Reduction

Watch for signs of overtreatment 1, 5:

• Rapid or irregular heartbeat, chest pain
• Tremors, nervousness, insomnia
• Unexplained weight loss
• Heat intolerance, excessive sweating
• New onset atrial fibrillation (especially if elderly)
• Accelerated bone loss (especially postmenopausal women)

Action Items

1. Immediately verify the FT4 result with your laboratory—confirm the actual value and correct units
2. If FT4 is truly abnormal, contact your prescribing physician before taking your next dose
3. If FT4 was a reporting error and is actually normal, continue current doses
4. Ensure you're taking medications correctly: levothyroxine 30-60 minutes before breakfast on empty stomach, separated from calcium, iron, and other interfering substances 1
5. Consider whether combination therapy is still necessary—discuss with your physician if symptoms have resolved, as levothyroxine monotherapy is preferred when effective 2